New insights into pleural mesothelioma
Studies reveal promising evidence for the more precise tailoring of immunotherapy and the role of AI in improving response evaluation
Future holds significant potential for advancement in immunotherapy of brain tumours
Results presented from some studies are a signal of an active area of research which is investigating not only immune checkpoint inhibitors but also vaccines and cellular therapies, although there are no immunotherapy treatments currently approved.
Study results further support the use of neoadjuvant immunotherapy in dMMR colon cancer
Three-year disease-free survival data from NICHE-2 and findings from NICHE-3 add to current knowledge on the benefits of immune checkpoint inhibition in this setting
Adding lenvatinib and pembrolizumab to transarterial chemoembolization improves progression-free survival in hepatocellular carcinoma
Positive data presented from the LEAP-012 study for intermediate-stage disease, but it is still unclear how these will influence clinical practice
Pembrolizumab plus concurrent chemoradiotherapy extends survival in locally advanced cervical cancer
New study findings support this treatment strategy as a new standard of care for patients with high-risk, locally advanced cervical cancer
Addition of immunotherapy to chemotherapy improves progression-free survival in anal canal
The PODIUM-303 study shows practice-changing results for patients with unresectable locally recurrent or metastatic squamous cell carcinoma of the anal canal
Long-term survival benefits reported with neoadjuvant immunotherapy combinations in stage III melanoma
Neoadjuvant immunotherapy combinations were associated with high long-term survival rates and were superior to adjuvant nivolumab in patients with resectable melanoma, according to a phase III study and analysis of pooled studies
Taxane- and anthracycline-sparing regimens show promise in high-risk, early-stage breast cancer
High rates of pathological complete response were reported with neoadjuvant datopotamab deruxtecan plus durvalumab in patients with specific subtypes of breast cancer and at high risk of recurrence
First-line immunotherapy combination improves overall survival in HER2-positive metastatic G/GEJ adenocarcinoma
Final analysis of the KEYNOTE-811 trial reports positive findings when adding pembrolizumab to trastuzumab and chemotherapy in treatment-naïve patients
Further support for durvalumab consolidation as a new standard of care in limited-stage SCLC
Subgroup analyses from the ADRIATIC study support previous practice-changing findings